Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women
Name:
35418701.pdf
Size:
1.290Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Wang, X.Kapoor, P. M.
Auer, P. L.
Dennis, J.
Dunning, A. M.
Wang, Q.
Lush, M.
Michailidou, K.
Bolla, M. K.
Aronson, K. J.
Murphy, R. A.
Brooks-Wilson, A.
Lee, D. G.
Cordina-Duverger, E.
Guénel, P.
Truong, T.
Mulot, C.
Teras, L. R.
Patel, A. V.
Dossus, L.
Kaaks, R.
Hoppe, R.
Lo, W. Y.
Brüning, T.
Hamann, U.
Czene, K.
Gabrielson, M.
Hall, P.
Eriksson, M.
Jung, A.
Becher, H.
Couch, F. J.
Larson, N. L.
Olson, J. E.
Ruddy, K. J.
Giles, G. G.
MacInnis, R. J.
Southey, M. C.
Le Marchand, L.
Wilkens, L. R.
Haiman, C. A.
Olsson, H.
Augustinsson, A.
Krüger, U.
Wagner, P.
Scott, C.
Winham, S. J.
Vachon, C. M.
Perou, C. M.
Olshan, A. F.
Troester, M. A.
Hunter, D. J.
Eliassen, H. A.
Tamimi, R. M.
Brantley, K.
Andrulis, I. L.
Figueroa, J.
Chanock, S. J.
Ahearn, T. U.
García-Closas, M.
Evans, G. D.
Newman, W. G.
van Veen, E. M.
Howell, Anthony
Wolk, A.
Håkansson, N.
Anton-Culver, H.
Ziogas, A.
Jones, M. E.
Orr, N.
Schoemaker, M. J.
Swerdlow, A. J.
Kitahara, C. M.
Linet, M.
Prentice, R. L.
Easton, D. F.
Milne, R. L.
Kraft, P.
Chang-Claude, J.
Lindström, S.
Affiliation
Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.Issue Date
2022
Metadata
Show full item recordAbstract
Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values < 5 × 10-8 as genome-wide significant, and p-values < 1 × 10-5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants. of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values < 1 × 105. The strongest evidence was found for rs4674019 (p-value = 2.27 × 10-7), which showed genome-wide significant interaction (p-value = 3.8 × 10-8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen-progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT-breast cancer risk association.Citation
Wang X, Kapoor PM, Auer PL, Dennis J, Dunning AM, Wang Q, et al. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Vol. 12, Scientific Reports. Springer Science and Business Media LLC; 2022.Journal
Scientific ReportsDOI
10.1038/s41598-022-10121-2PubMed ID
35418701Additional Links
https://dx.doi.org/10.1038/s41598-022-10121-2Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41598-022-10121-2
Scopus Count
Collections
Related articles
- A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.
- Authors: Hein R, Flesch-Janys D, Dahmen N, Beckmann L, Lindström S, Schoof N, Czene K, Mittelstraß K, Illig T, Seibold P, Behrens S, Humphreys K, Li J, Liu J, Olson JE, Wang X, Hankinson SE, Truong T, Menegaux F, Dos Santos Silva I, Johnson N, GENICA Network, Chen ST, Yu JC, Ziogas A, Kataja V, Kosma VM, Mannermaa A, Anton-Culver H, Shen CY, Brauch H, Peto J, Guénel P, Kraft P, Couch FJ, Easton DF, Hall P, Chang-Claude J
- Issue date: 2013 Apr
- Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
- Authors: DeBono NL, Robinson WR, Lund JL, Tse CK, Moorman PG, Olshan AF, Troester MA
- Issue date: 2018 Mar
- Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
- Authors: Salagame U, Banks E, O'Connell DL, Egger S, Canfell K
- Issue date: 2018
- Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium.
- Authors: Gaudet MM, Barrdahl M, Lindström S, Travis RC, Auer PL, Buring JE, Chanock SJ, Eliassen AH, Gapstur SM, Giles GG, Gunter M, Haiman C, Hunter DJ, Joshi AD, Kaaks R, Khaw KT, Lee IM, Le Marchand L, Milne RL, Peeters PH, Sund M, Tamimi R, Trichopoulou A, Weiderpass E, Yang XR, Prentice RL, Feigelson HS, Canzian F, Kraft P
- Issue date: 2016 Feb
- Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.
- Authors: Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, Aschard H, Bolla MK, Wang J, Truong T, Cordina-Duverger E, Menegaux F, Brüning T, Harth V, GENICA Network, Severi G, Baglietto L, Southey M, Chanock SJ, Lissowska J, Figueroa JD, Eriksson M, Humpreys K, Darabi H, Olson JE, Stevens KN, Vachon CM, Knight JA, Glendon G, Mulligan AM, Ashworth A, Orr N, Schoemaker M, Webb PM, kConFab Investigators, AOCS Management Group, Guénel P, Brauch H, Giles G, García-Closas M, Czene K, Chenevix-Trench G, Couch FJ, Andrulis IL, Swerdlow A, Hunter DJ, Flesch-Janys D, Easton DF, Hall P, Nevanlinna H, Kraft P, Chang-Claude J, Breast Cancer Association Consortium
- Issue date: 2013 Dec